Melanoma: Questions for the future

European Journal of Surgical Oncology

Volumn 22, Issue 2, 1996, Pages 130-133

  Thomas, J Meirion ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; DACARBAZINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; GENE THERAPY; HUMAN; LYMPH NODE BIOPSY; LYMPHADENECTOMY; MELANOMA; PRIORITY JOURNAL; SURGICAL TECHNIQUE;

EID: 0029864297     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(96)90515-6     Document Type: Article

References (28)

1. Timmons MJ. Malignant melanoma excision margins: plastic surgery audit in Britain and Ireland 1991, and a review. Br J Plast Surg 1993; 46: 525-31.
2. Veronesi U, Cascinelli N. Narrow excision (I cm margin): a safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126: 438-41.
3. Ross MI, Balch CM. The current management of cutaneous melanoma. Adv Surg 1991; 24: 139-200.
4. Timmons MJ, Thomas JM. The width of excision of cutaneous melanoma. Eur J Surg Oncol 1993; 19: 313-5.
5. Ball ABS, Thomas JM. Surgical management of malignant melanoma. Br Med Bull 1995; 51: 584-608.
6. Morton DL, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-9.
7. Morton DL, Wen D-R, Cochran AJ. Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy. Surg Clin North Am 1992; 1: 247-59.
8. Lee SM, Betticher DC, Thatcher N. Melanoma: chemotherapy. Br Med Bull 1995; 51: 609-30.
9. Bridgewater JA, Gore ME. Biological response modifiers in melanoma. Br Med Bull 1995; 51: 913-4.
10. Kirkwood J, et al. A randomized control trial of high-dose IFN alpha for high risk melanoma. Proc Ann Soc Clin Oncal 1993; 12: 390.
11. Cascinelli N, Buffalino R, MacKie R. Letter to the Editor. Lancet 1994; 343: 9134.
12. Cascinelli N. ASCO presentation. May 1995.
13. Eggermont AMM. Personal communication. 1996.
14. Hancock B. Personal communication. 1996.
15. Berd D, Sato T, Lattime ED, Maguire HC, Mastrangelo MJ. Immunisation with hapten-modified tumor cells: a strategy for the treatment of human melanoma. Am Assoc Cancer Res 1994; 35: 667-8.
16. Morton DL, Foshag LJ, Hoon DSB, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 463-82.
17. Mitchell MS. Active specific immunotherapy of melanoma. Br Med Bull 1995; 51: 631-46.
18. Livingston PO, Wong CY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomised trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12: 1036-44.
19. Peto J. (Royal Marsden Hospital and ICR Sutton, UK). Personal communication 1996.
20. Van der Bruggen C, Traversari C, Chomez P, Boon T. A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
21. Gansbacher B, Zier B, Daniels K, Cronin R, Bannerji R, Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorgenicity and induces protective immunity. J Exp Med 1990; 172: 1217-24.
22. Int J Cancer - reference on MAGE-3 from Boon and Marchant.
23. Rankin EB, Spits H, Orsini M, et al. A Phase I study of vaccination with autologous GM-CSF transduced and irradiated tumour cells in patients with advanced melanoma. Proc Am Soc Clin Oncol 1995; 226: A580.
24. Gore M, Collins M. (Royal Marsden Hospital London). Personal communication 1996.
25. Vile RG, Hart IR. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 1993; 53: 962-7.
26. Chen L, Ashe S, Brady WA, et al. Co-stimulation of antitumour immunity by the B7 counter receptor for the T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
27. Vile RG, Hart IR. Targeting of cytokine gene expression to malignant melanoma cells using tissue-specific promotor sequences. Ann Oncol 1994; 5(Suppl. 4): S59-S65.
28. Vile RG, Hart IR. Use of tissue-specific expression of the Herpes Simplex Virus thymidine kinase gene to inhibit growth of established murine melanoma following direct intratumoral injection of DNA. Cancer Res 1993; 53: 3860-4.